BriaCell Therapeutics (BCTX) said late Tuesday it priced a public offering of 5.4 million units at $5.59 per unit for total expected gross proceeds of $30 million.

Each unit consists of one common share and one warrant to purchase common shares at $6.93 per share. The company may also issue, in lieu of common shares, pre-funded warrants.

Net proceeds will be used for working capital, general corporate purposes, and for the advancement of business objectives, BriaCell said.

Closing of the offering is expected to occur this Thursday, subject to customary closing conditions.